Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record.

Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

Open access
Lai, Ching-Lung, Lau, Johnson Y. N., Wu, Pui-Chee, Ngan, Henry, Chung, Hau-Tim, Mitchell, Stuart J., Corbett, Timothy J., Chow, Anthony W. C., Lin, Hsiang-Ju·1993·Hepatology

Abstract

To evaluate the clinical efficacy of interferon-α in hepatocellular carcinoma, 71 adult Chinese patients with histologically proven inoperable hepatocellular carcinoma were randomized to receive recombinant interferon-α 2a (50 × 10 6 IU/m 2) intramuscularly three times a week (n = 35) or no antitumor therapy (n = 36). The survival of interferon-α-treated patients was significantly better than that of patients who received no antitumor therapy (p = 0.0471); median lengths of survival were 14.5 and 7.5 wk, respectively. Objective tumor regression greater than 50% was observed in 31.4% (11 of 35) of patients receiving interferon-α. Interferon-α induced tumor regression greater than 50% in 11(31.4%) patients. Compared with the group receiving no antitumor therapy, the interferon-α therapy group had more tumor regression (p < 0.0001) and less tumor progression (p = 0.001). This high-dose interferon-α therapy was relatively well tolerated; only 34.3% of patients required reduction of dosage by one third or one half because of persistent fatigue. Two patients with diabetes mellitus (one also had tabes dorsalis) exhibited mental deterioration that might have been partially attributable to interferon-α therapy. We conclude that interferon-α is useful in a proportion of Chinese patients with inoperable hepatocellular carcinoma, both in prolonging survival and in inducing tumor regression. (Hepatology 1993;17:389-394.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.1840170307

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 221

Metadata

Authors
Lai, C.-L., Lau, J. Y. N., Wu, P.-C., Ngan, H., Chung, H.-T., Mitchell, S. J., Corbett, T. J., Chow, A. W. C., & Lin, H.-J.
Venue
Hepatology
Published
1993-03
Volume
17
Issue
3
Pages
389-394
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2085664147
Cited by
221
References
0
FWCI
3.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial. https://app.cochat.ai/papers/10.1002/hep.1840170307
The paper
Lai, C.-L., Lau, J. Y. N., Wu, P.-C., Ngan, H., Chung, H.-T., Mitchell, S. J., Corbett, T. J., Chow, A. W. C., & Lin, H.-J. (1993). Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial. Hepatology. https://doi.org/10.1002/hep.1840170307

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.